Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Research Performed at PRMA Expands Breast Reconstruction Knowledge
  • USA - English


News provided by

PRMA Plastic Surgery

Apr 21, 2015, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Youtube
Youtube

San Antonio, TX (PRWEB) April 21, 2015 -- As nationally recognized leaders in breast reconstruction, PRMA is actively involved in various components of breast reconstruction research spanning both clinical and basic science fields.

"Breast reconstruction research continues to significantly contribute to better patient outcomes following mastectomy. Despite recent advances, many unanswered questions remain requiring continuous multifaceted efforts in order to provide patients with optimal results," says Dr. Oscar Ochoa emphasizing the importance of PRMA's research efforts.

With added knowledge will come better treatment and reconstructive options for our patients, which is our ultimate goal," says Dr. Gary Arishita.

Post this

In an effort to better characterize their broad involvement in ongoing research, a brief overview of a few of the current initiatives are presented:

Re-excision of residual cancer following mastectomy and reconstruction – In a small percentage of women undergoing mastectomy for breast cancer or pre-malignant lesions, residual cancer cells may be left behind at the previous location of the lesion(s). Unfortunately, this is not usually discovered until thorough evaluation by a pathologist is completed a few days later. Treatment of this residual cancer is controversial, especially after breast reconstruction has been performed immediately following mastectomy. One option is radiation to the reconstructed breast in an effort to “kill off” any residual cancer cells. Naturally, radiation can lead to unwanted short and long-term complications. PRMA promotes an alternative option where patients undergo an additional surgical procedure where the residual cancer cells are directly excised. Outcomes following this unique re-excision procedure related to reconstruction complications, cosmetic outcome, and most importantly, cancer recurrence are being submitted for publication.

Patient reported outcomes following breast reconstruction – For reconstructive surgeons, the ultimate goal is to facilitate a patient’s recovery from breast cancer. By providing patients with a sense of “wholeness” through breast reconstruction, patients are less likely to experience a lingering sense of loss, depression, or anxiety in social or intimate situations. Through standardized questionnaires given to patients before and after surgery, PRMA has been able to identify specific factors such as age, body mass index, patient ethnicity, and other variables that are associated with obtaining a successful result from a patient’s point of view.

Radiation to the breast after immediate breast reconstruction – Breast reconstruction at the same time of mastectomy (immediate breast reconstruction) is currently recommended only in early stage breast cancer (cancer < 5cm in diameter, < 4 lymph nodes involved). If the breast cancer is diagnosed at an advanced stage and will require radiation even after mastectomy, reconstruction is not performed immediately but delayed until a later time (delayed breast reconstruction), which eliminates the psychosocial benefits of immediate reconstruction. Delaying the reconstruction until radiation is completed theoretically decreases radiation injury to the flap of tissue used to reconstruct the breast. This dogma was established many years ago when radiation delivery techniques were rudimentary and very imprecise. Since that time, radiation delivery techniques have advanced significantly allowing only the target tissue to be treated with radiation while sparing adjacent harmless tissue such as the reconstruction flap. Although PRMA still adheres to these recommendations, some patients have undergone immediate breast reconstruction with subsequent recommendations to receive radiation due to a larger-than-expected cancer or numerous involved lymph nodes identified after mastectomy. PRMA is currently performing studies to evaluate the radiation-induced complications experienced by these unique patients on the side of radiation compared to non-radiated reconstructed breasts. It is possible, due to advancements in radiation delivery techniques, radiated reconstructed breasts may have a similar complication profile than non-radiated breast reconstructions. If true, immediate breast reconstruction could now be offered to patients with advanced breast cancer eliminating the need for delayed breast reconstruction.

Vascularized lymph node transfer – Upper extremity lymphedema is a tremendously debilitating complication of breast cancer treatment due to axillary lymph node removal. The affected limb becomes swollen impairing function due to lack of lymphatic fluid drainage. At PRMA, patients with lymphedema are treated with an adjunct procedure at the time of breast reconstruction where lymph nodes, normally located in the groin area, are transferred (en bloc) with the abdominal tissue into the affected axilla. With addition of groin lymph nodes into the affected axilla, re-establishment of lymph drainage may be promoted alleviating swelling and improving function. Currently, PRMA surgeons are evaluating the objective benefit (and possible complications) of such lymph node transfer procedures.

Genetic mutations promoting hereditary breast cancer – The fields of molecular biology and genetics have contributed significantly to our current understanding of breast cancer. With identification of mutations in certain genes, lifetime risk of development of breast cancer in affected individuals is as high as 90%. Young women that are diagnosed with one of these genetic mutations are often undergoing preventative mastectomies in order to eliminate the possibility of developing breast cancer in the future. The current understanding as to how these genetic mutations predispose an individual to develop breast cancer is still lacking. PRMA is collaborating with UT Health Science Center San Antonio in a joint investigation utilizing the latest molecular techniques on PRMA patient tissue samples in order to better elucidate the mechanism involved in the development of breast cancer.

“We certainly have a lot to learn and are always striving for the best for our patients. With added knowledge will come better treatment and reconstructive options for our patients, which is our ultimate goal," says Dr. Gary Arishita.

About PRMA
PRMA Plastic Surgery in San Antonio, Texas, specializes in state-of-the-art breast reconstruction. Procedures offered include the DIEP flap, SIEA flap, GAP flap, TUG flap, fat grafting, Alloderm One-Step, vascularized lymph node transfer and nipple-sparing mastectomy. PRMA is In-Network for most US insurance plans and routinely welcomes patients from across and outside the US. Connect with other patients in our breast reconstruction community on Facebook.

Courtney Floyd, PRMA Plastic Surgery, http://PRMA-enhance.com, +1 (800) 692-5565, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.